A phase 1b study of HC-7366 plus Welireg for advanced clear cell renal cell carcinoma has completed the dose escalation ...

Sickle cell disease (SCD) altered CD8+ T-cell chromatin architecture, triggering ferroptosis and weakening antitumor immunity ...

Allogene Therapeutics continues to advance its pipeline, with notable progress in key clinical trials and upcoming data ...

Kidney fibrosis, a common endpoint of chronic kidney disease (CKD), is strongly linked to aging, with cellular senescence ...

Naomi Haas, MD, discusses the 5-year follow-up of the KEYNOTE-564 study being presented at the 2025 ASCO Annual Meeting.

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Bone is a common site for metastasis of solid cancers, but histological and molecular features of bone metastases are not ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...

A woman with an erratic lifestyle and history of alcohol misuse bled to death in her home after unpicking a dialysis graft ...

Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC ...

Individuals with both sickle cell disease (SCD) and sickle cell trait are at higher risk than others of developing renal medullary cancer (RMC), the rarest and deadliest subtype of kidney cancer.